On the public citation graph

Drug patents: the evergreening problem

https://doi.org/10.1503/cmaj.109-4466
0 signed · 41 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3143243openalex-extracted
Investor-State Arbitration: A New Threat to Global Access to Affordable Medicine
inferred← citeshttps://doi.org/10.1007/978-3-031-17960-0_4openalex-snapshot
Obstacles to Innovative Activities: Case of the Floriculture Sector in Ecuador
inferred← citeshttps://doi.org/10.1007/978-3-319-74319-6_635openalex-snapshot
Pharmaceutical Patent Protection: Key Issues and Dilemmas
inferred← citeshttps://doi.org/10.1007/978-3-319-74336-3_635-1openalex-snapshot
Pharmaceutical Patent Protection: Key Issues and Dilemmas
inferred← citeshttps://doi.org/10.1007/s40005-024-00673-yopenalex-snapshot
Preformulation and evaluation of multi-layer tablets
inferred← citeshttps://doi.org/10.1016/j.anclin.2023.12.001openalex-snapshot
Public Good versus Private “Goods”
inferred← citeshttps://doi.org/10.1016/j.drudis.2025.104453openalex-snapshot
Commercialization of cell and gene therapy in Canada: Current landscape, challenges and opportunities
inferred← citeshttps://doi.org/10.1016/j.hlc.2022.01.010openalex-snapshot
Are We There Yet? Exploring the Use of Single-Pill Combination Therapy in the Management of Raised Blood Pressure in Australia
inferred← citeshttps://doi.org/10.1016/j.techfore.2026.124539openalex-snapshot
A structural-evolutionary rationale for public support of private technological innovation
inferred← citeshttps://doi.org/10.1016/j.worlddev.2022.105881openalex-snapshot
Why the Great Food Transformation may not happen – A deep-dive into our food systems’ political economy, controversies and politics of evidence
inferred← citeshttps://doi.org/10.1016/s2055-6640(20)30286-7openalex-snapshot
The complex legal and ethical issues related to generic medications. Viral hepatitis: a case study
inferred← citeshttps://doi.org/10.1017/asr.2022.154openalex-snapshot
Coloniality of Waithood: Africa’s Wait for COVID-19 Vaccines amid COVAX and TRIPS
inferred← citeshttps://doi.org/10.1080/09505431.2025.2532769openalex-snapshot
Biologics of resistance: Open Insulin and the limits of bioengineering-as-activism
inferred← citeshttps://doi.org/10.1093/jac/dkae480openalex-snapshot
Safety and efficacy of long-acting cabotegravir/rilpivirine versus standard oral antiretroviral therapy: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1111/jch.14009openalex-snapshot
Two‐drug fixed‐dose combinations of blood pressure‐lowering drugs as WHO essential medicines: An overview of efficacy, safety, and cost
inferred← citeshttps://doi.org/10.1111/jwip.12099openalex-snapshot
Japan's emerging role in the global pharmaceutical intellectual property regime: A tale of two trade agreements
inferred← citeshttps://doi.org/10.1126/sciadv.1500439openalex-snapshot
Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine
inferred← citeshttps://doi.org/10.1136/bmjebm-2019-111204openalex-snapshot
Digital aripiprazole or digital evergreening? A systematic review of the evidence and its dissemination in the scientific literature and in the media
inferred← citeshttps://doi.org/10.1177/17411343261459367openalex-snapshot
Beyond primary patents: Strategic intellectual property frameworks for sustained pharmaceutical market dominance in US & EU
inferred← citeshttps://doi.org/10.1377/hlthaff.2015.0375openalex-snapshot
Overcoming Obstacles To Enable Access To Medicines For Noncommunicable Diseases In Poor Countries
inferred← citeshttps://doi.org/10.1503/cmaj.130992openalex-snapshot
Limiting “evergreening” for a better balance of drug innovation incentives
inferred← citeshttps://doi.org/10.15406/mojbb.2017.03.00053openalex-snapshot
Drug Affordability in India - an Analytical Review
inferred← citeshttps://doi.org/10.1596/26801openalex-snapshot
Medicines Regulatory Systems and Scope for Regulatory Harmonization in Southeast Asia
inferred← citeshttps://doi.org/10.18034/ajtp.v8i2.564openalex-snapshot
The COVID-19 Vaccine and the Future of International Laws in Business, Travel, and Trade
inferred← citeshttps://doi.org/10.18060/25507openalex-snapshot
Leaving the Evergreening Problem to the Patent Experts--The USPTO, the PTAB, and the Federal Circuit
inferred← citeshttps://doi.org/10.18103/mra.v11i6.3830openalex-snapshot
The Relevance of Regional Specificities of Intellectual Property Regulations for Pharmaceutical Industries: Brazilian Law Changes That Immediately Affected Crucial US-Pharmaceutical Patents with Correspondents in Brazil
inferred← citeshttps://doi.org/10.2174/1872208317666230111105223openalex-snapshot
Patent and Marketing Exclusivities 101 for Drug Developers
inferred← citeshttps://doi.org/10.2217/rme-2017-0144openalex-snapshot
An Endogenous Explanation of Growth: Direct-to-Consumer Stem Cell Therapies in PR China, India and the USA
inferred← citeshttps://doi.org/10.24018/ejpolitics.2023.2.2.83openalex-snapshot
Towards Better Balanced IPRs: Improving Access to Health through Better Access to Education
inferred← citeshttps://doi.org/10.32352/0367-3057.6.25.03openalex-snapshot
Retrospective analysis of legislative regulation of advertising of medicinal products as an object of legal protection
inferred← citeshttps://doi.org/10.33320/maced.pharm.bull.2022.68.03.254openalex-snapshot
Medical use patents of antineoplastics: new trend of ‘evergreening’ and prevention generics on the market
inferred← citeshttps://doi.org/10.33731/32020.214636openalex-snapshot
THE EVERGREENING STUDY OF UKRAINIAN PHARMACEUTICAL MARKET
inferred← citeshttps://doi.org/10.3386/w23900openalex-snapshot
Measuring the Potential Health Impact of Personalized Medicine: Evidence from MS Treatments
inferred← citeshttps://doi.org/10.3390/antibiotics10091096openalex-snapshot
Comparison of Pharmaceutical Characteristics between Brand-Name Meropenem and Its Generics
inferred← citeshttps://doi.org/10.3390/molecules29184475openalex-snapshot
Some Aspects and Convergence of Human and Veterinary Drug Repositioning
inferred← citeshttps://doi.org/10.34246/ahbvuhfd.979225openalex-snapshot
COVID-19 AŞILARI ÜZERİNDEKİ PATENT HAKKININ KAPSAMININ KAMU SAĞLIĞI AÇISINDAN DEĞERLENDİRİLMESİ
inferred← citeshttps://doi.org/10.4045/tidsskr.16.1149openalex-snapshot
Skal legemiddelfirmaene bestemme hvilke studier som blir gjort?
inferred← citeshttps://doi.org/10.4103/ayu.ayu_71_23openalex-snapshot
Herbal pharmaceutical patent protection: Illustrative evidence on prosecution stages and section 3 [d] implication of Indian Patent Act
inferred← citeshttps://doi.org/10.4155/ppa-2018-0024openalex-snapshot
Discussions on the New Molecular Formula and New Molecular Entity Definitions of Pharmaceutical Innovation
inferred← citeshttps://doi.org/10.4155/ppa-2023-0009openalex-snapshot
Patents, Pharmaceutical Industry and Healthcare
inferred← citeshttps://doi.org/10.5639/gabij.2022.1102.011openalex-snapshot
A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.